These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6634455)

  • 21. The effect of somatostatin on the rise of growth hormone and glucagon secretion induced by arginine and L-dopa in diabetic patients.
    Hansen AP; Christensen SE; Lundbaek K
    Scand J Clin Lab Invest; 1975 May; 35(3):205-10. PubMed ID: 1153917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Propranolol enhancement of L-DOPA induced growth hormone stimulation.
    Camanni F; Massara F; Molinatti GM
    Biomedicine; 1974 Jun; 21(6):241-3. PubMed ID: 4441586
    [No Abstract]   [Full Text] [Related]  

  • 23. Secretion of growth hormone after L-dopa stimulation in patients with renal failure treated with dialyses.
    Kuska J; Kokot F; Sledziński Z
    Acta Med Pol; 1979; 20(3):217-26. PubMed ID: 517160
    [No Abstract]   [Full Text] [Related]  

  • 24. Levodopa-stimulated growth hormone secretion and diabetic retinopathy.
    Holland PM; Landers MB; Lebovitz HE; Wolbarsht ML
    Am J Ophthalmol; 1976 Oct; 82(4):612-8. PubMed ID: 970425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyroid function and growth hormone secretion in amitriptyline-treated depression.
    Leichter SB; Kirstein L; Martin ND
    Am J Psychiatry; 1977 Nov; 134(11):1270-2. PubMed ID: 910982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Stimulation of growth hormone (HGH) with L-dopa].
    Gosselin L; Bolduc R; Verreault R
    Union Med Can; 1974 Sep; 103(9):1552-6. PubMed ID: 4439528
    [No Abstract]   [Full Text] [Related]  

  • 27. [Ratio of somatostatin-glucagon secretion in diabetes mellitus].
    Kostiuk EP
    Fiziol Zh (1978); 1985; 31(2):195-201. PubMed ID: 2860024
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effect of pimozide on the prolactin and somatotropin responses to L-dopa, and on the somatotropin response to hypoglycemia (author's transl)].
    Hernández JM; Morales SE; López MA
    Rev Invest Clin; 1977; 29(3):201-7. PubMed ID: 918416
    [No Abstract]   [Full Text] [Related]  

  • 29. L-dopa stimulation at growth hormone release in normal subjects and in patients with Sheehan's syndrome.
    Himathongkam T; Tiyapan A; Rajatanavin R; Pitchayayothin N
    J Med Assoc Thai; 1981 Jan; 64(1):19-25. PubMed ID: 7217816
    [No Abstract]   [Full Text] [Related]  

  • 30. L-dopa stimulation of glucagon secretion in man.
    Rayfield EJ; George DT; Eichner HL; Hsu TH
    N Engl J Med; 1975 Sep; 293(12):589-91. PubMed ID: 1152893
    [No Abstract]   [Full Text] [Related]  

  • 31. Differential effects of L-dopa and apomorphine on glucagon secretion in man: evidence against central dopaminergic stimulation of glucagon.
    Lorenzi M; Tsalikian E; Bohannon NV; Gerich JE; Karam JH; Forsham PH
    J Clin Endocrinol Metab; 1977 Dec; 45(6):1154-8. PubMed ID: 591612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonidine and GH secretion in insulin dependent diabetes (IDD).
    Speroni G; Ceda GP; Capretti L; Valenti G
    Horm Metab Res; 1983 Jan; 15(1):46-7. PubMed ID: 6299919
    [No Abstract]   [Full Text] [Related]  

  • 33. On the mechanism of hyperglycemia and stimulation of growth hormone secretion by L-dopa.
    Hampshire J; Moraru E; Altszuler N
    Pharmacology; 1978; 17(3):138-48. PubMed ID: 704657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes mellitus and healing of closed fractures.
    Herskind AM; Christensen K; Nørgaard-Andersen K; Andersen JF
    Diabete Metab; 1992; 18(1):63-4. PubMed ID: 1563540
    [No Abstract]   [Full Text] [Related]  

  • 35. Dopamine inhibition of stimulated growth hormone secretion: evidence for dopaminergic modulation of insulin- and L-dopa-induced growth hormone secretion in man.
    Woolf PD; Lantigua R; Lee LA
    J Clin Endocrinol Metab; 1979 Sep; 49(3):326-30. PubMed ID: 468965
    [No Abstract]   [Full Text] [Related]  

  • 36. [Amantadine potentiation of G.H. relase evoked by L-dopa and its inhibition by nonesterified fatty acids].
    Cabezas-Cerrato J; Casanueva Freijo F; Villanueva Aranguren L; Avila C; Fernández-Cruz A
    Rev Clin Esp; 1977 May; 145(3):165-8. PubMed ID: 866739
    [No Abstract]   [Full Text] [Related]  

  • 37. The dynamics of growth hormone secretion in various stages of diabetic microangiopathy development.
    Sieradzki J; Mruk K; Bryk E
    Acta Med Pol; 1977; 18(1):47-54. PubMed ID: 855680
    [No Abstract]   [Full Text] [Related]  

  • 38. [Differential diagnosis of growth disorders based on the determination of growth hormone secretion following administration of L-dopa].
    Gembicki M; Kosowicz J; Sobieszczyk S
    Pol Arch Med Wewn; 1975 Aug; 54(2):147-52. PubMed ID: 1161535
    [No Abstract]   [Full Text] [Related]  

  • 39. Syndrome X: a syndrome of insulin resistance. Epidemiological and clinical evidence.
    Wajchenberg BL; Malerbi DA; Rocha MS; Lerario AC; Santomauro AT
    Diabetes Metab Rev; 1994 Apr; 10(1):19-29. PubMed ID: 7956673
    [No Abstract]   [Full Text] [Related]  

  • 40. Reduced growth hormone response to L-dopa and pyridostigmine in obesity.
    Lee EJ; Kim KR; Lee KM; Lim SK; Lee HC; Lee JH; Lee DJ; Huh KB
    Int J Obes Relat Metab Disord; 1994 Jul; 18(7):465-8. PubMed ID: 7920871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.